MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

65.85 +0.47 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,522,823
Open 65.82
Bid (Size) 65.70 (3)
Ask (Size) 66.85 (1)
Prev. Close 65.38
Today's Range 64.91 - 67.31
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
Via Investor's Business Daily

Performance

YTD
+260.23%
+260.23%
1 Month
-1.86%
-1.86%
3 Month
+32.12%
+32.12%
6 Month
-0.93%
-0.93%
1 Year
+514.27%
+514.27%

More News

Read More
Where Will Viking Therapeutics Be in 5 Years?
Via The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
The Ultimate Biotech Stock to Buy With $100 Right Now
Via The Motley Fool
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
Viking Therapeutics Unusual Options Activity
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Viking Therapeutics Unusual Options Activity For September 24
Via Benzinga
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Via Benzinga
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
Why Viking Therapeutics Stock Topped the Market Today
Via The Motley Fool
Is Viking Therapeutics Stock a Buy?
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
Via The Motley Fool
Is Viking Therapeutics Ready For Another Surge?
Via MarketBeat
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
Via Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Via The Motley Fool
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Via MarketBeat
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story